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1. Introduction 
By virtue of the dynamic nature of the scientific process, the description of the pathogenesis 
of a disease is always a work in progress. Each day new research shapes and refines our 
understanding of disease processes; an attempt to describe the current scientific 
understanding provides merely a snapshot of a body of knowledge that is constantly 
changing. However, characterizing a disease using homeostatic and physiological terms 
allows the creation of a framework to convey the most up-to-date theories while 
maintaining the potential for their evolution. 
The complex nature of psoriasis can similarly be unveiled through understanding the 
historical context of our current understanding, examining prevailing hypotheses, and 
extrapolating horizons for new research. To develop a framework for understanding the 
pathogenesis of psoriasis and its evolution, the first perception to be changed is the 
prevalent view of the immune system. The general notion of the immune system as a 
defense arrangement that protects us against the microorganisms must be changed. This 
view results from a reduction of the process itself and, as mentioned by Dr. Nelson Vaz, are 
features derived from the birth of the immunology (Vaz et al., 2006). Immunology, as 
scientific field, is new in the history of medicine. Immunology developed in a century 
marked by the First and Second World War and Cold War tension. Hence, many models to 
exemplify the immunological concepts were simplified and described in relation to war 
affairs to facilitate the understanding of this science. In this model, if a microorganism 
attacks a human being, the individual advocates the use of the immune system to 
counteract. Another simple aspect is the teleology that prevails in the immune science. For 
example, the T lymphocyte exists to kill cells infected with intracellular parasites. This 
model full of logic and consequences does not apply in many other areas of medical and 
non-medical sciences. As such, it is necessary to move to a new approach to describing the 
relationship between the immune system and environment. In this new paradigm, the 
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immune system does not react, but rather interacts with the environment, and this contact is 
made through the skin and mucous membranes. This interaction, causal or not, can have 
different results. In most cases, there is a balance, imperceptible to other sensory systems, 
which is characterized by the integrity of what we call health. Thus, homeostasis disorders 
or imbalances lead to disease. This seems obvious when written, but this search for stability 
has continuity for the duration of the life of a given organism. If we consider the immune 
system a sensorial system, it interacts with the modifications of the environment, detects this 
information of change, and responds with adjustments to maintain homeostasis. You might 
reduce this view by comparing it to an engine that runs under different types of fuel 
mixture. It detects the different fuel composition and changes the compression ratio of the 
cylinder for better efficiency to keep the car moving. 
For better observation of this psoriasis pathogenesis, we will make a technical simulation of 
the immune system in a specific situation. This simulation will cover various aspects of 
immune response, spanning from the beginning of the inflammatory response, to specific 
immune response through the development of psoriasis. Here, under a historical 
perspective and comparing with a chess game, the main objective is to provide insights on 
the central role of some of these cytokines and immunological pathways in psoriasis 
pathophysiology. Through this, the aim is to explain some facts of modern 
immunodermatology that might be useful for clinicians to understand the basis of the 
immunology of psoriasis. Moreover, an important goal is to dispel some misinformation 
that might have a negative impact on the use of new immunomodulators and medications 
available for use by physicians. Treatment basis and therapeutic response experience 
strongly supports the use of immunomodulators as important modalities in the treatment of 
psoriatic arthritis and plaque psoriasis. Studies with these therapeutic agents, which act in 
different steps of the psoriatic inflammatory cascade, have also shown significant efficacy. 
(Scarpa et al., 2010).  
Directly targeting this inflammatory cascade, blocking specific cytokines is a modern 
treatment option for psoriasis and other autoimmune diseases (Lima et al., 2009b). The 
rationale for this therapy arises from pathophysiology; in different autoimmune diseases 
there is an increase in production of proinflammatory cytokines by the immune system. 
Inflammatory cytokines, like many other cytokines, have an important role in both 
maintaining health and participating in disease manifestation (Feldmann et al., 1998). This 
chapter discusses the pivotal role of some of these cytokines in psoriasis pathophysiology, 
how our understanding of its mechanism evolved, and how blocking the effect of a specific 
cytokine might substantially improve the disease condition. 
2. Pre-biologic immunological history of psoriasis 
Psoriasis is a common skin disease with extra-cutaneous manifestations. It is characterized 
by chronic inflammation of the skin with changes in the maturation of keratinocytes, which 
is manifested by the hyperproliferation of the epidermis. Moreover, inflammatory reaction 
can be found in other systems of the same patient. However, this disease is mediated by T 
lymphocytes, orchestrated by orchestration multigenic and environmental factors. The 
altered immune system is essential for the inflammation present in both the skin and other 
organs. A concept of a multi-systemic disorder involving different organs of the patient is 
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actual and reflects a better understanding of the complex pathophysiology of this disease 
(Scarpa et al., 2010). 
The concept of biological therapy for psoriasis has been derived from its etiopathogenesis. 
As in a chess game, these new forms of treatment have evolved from an integration of the 
knowledge of interactions between the immune system cells (pieces) and its cytokines 
(movements) that initiates the pathologic processes and ultimately leads to the development 
of the clinical features of psoriasis. 
In ancient records, the initial causes of psoriasis were attributed to multiple sources ranging 
from the divine power to racial associations (Squire, 1873). An unknown infectious 
organism was indicated as a source of psoriasis in 1927 (Heaney, 1927). Later, its etiology 
was described as primarily and essentially an epidermal problem, independent of 
immunologic phenomena (Ingram, 1953). The main objective of cytotoxic drugs developed 
in the 20th century, such as methotrexate, was to reduce keratinocyte proliferation. 
Immunological studies on psoriatic patients identified changes in humoral immune 
reactions as part of the overall problem but not the cause (Aswaq et al., 1960; Harber et al., 
1962). Efficacy of the cytotoxic drugs in the late 1960s paved the road for ideas about the role 
of the immune system in psoriasis (Harris, 1971; Landau et al., 1965). Further investigations 
in the 1970s revealed the role of immunologic factors in psoriasis. However, the dominant 
thought was that psoriasis was a disease of faulty epidermopoiesis due to impaired 
autocontrol mechanisms (Shuster, 1971). Hunter et al. wrote “More work on cell turnover 
and its regulation will give the clue to psoriasis” (Hunter et al., 1974). 
Other studies in the 1970s revealed the role of immunologic factors in psoriasis. 
Histopathologic examination of psoriatic lesions showed a striking resemblance to cellular 
inflammatory reactions observed in allergic contact dermatitis (Braun-Falco & Christophers, 
1974). A selective immunosuppressant effect was the initial hypothesis used to describe the 
pathological cellular immune response (Krueger et al., 1978). Soon thereafter, the discovery 
of a soluble factor that played an important role in keratinocyte proliferation helped to form 
the cytokine-based theory for the induction/maintenance of the inflammatory and 
proliferative cascades of psoriatic lesions (Krueger & Jederberg, 1980). Subsequently, an 
integrated theory explaining the etiopathogenesis of psoriasis came into play: in a 
genetically susceptible patient, immunological factors trigger rapid turnover in the 
epidermis resulting in development of psoriasis (Champion, 1981). 
The fundamental confirmation that any defect of the skin is not sufficient by itself to 
maintain a psoriatic lesion occurred in the subsequent decade. Some studies confirmed that 
T cells and soluble factors could stimulate keratinocyte proliferation. Immunophenotyping 
of psoriatic lesions showed mixed T lymphocyte (TL) cell populations (CD4 and CD8) and 
Langerhans cells (LCs) distinct from normal skin (Bos et al., 1983). This cellular infiltrate 
changed with topical or systemic treatment (Baker et al., 1985; Bos & Krieg, 1985). In another 
study, failure of plasma exchange and leukapheresis ruled out the major participation of 
humoral immune system in the pathogenesis of psoriasis (Lieden & Skogh, 1986). Thus, the 
cellular arm of the immune system was implicated in psoriasis for the first time during the 
1980s (Valdimarsson et al., 1986). 
During the 1990s, research on immunopathogenesis of psoriasis thus focused on the cellular 
and the cytokine components of the immune system. Researchers observed that an influx of 
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activated T lymphocytes, mainly CD4+, HLA-DR+, Interleukin (IL)-2 receptor - CD25+ T 
cells, was one of the earliest events of psoriasis (Schlaak et al., 1994). Based on Mosmman 
and Coffman’s publication (Mosmann et al., 1986), these T lymphocytes were classified as T 
helper (Th) type 1 cytokine producers (Th1) (Austin et al., 1999). They produce Interferon 
(IFN)-┛, IL-2, and Tumor Necrosis Factor (TNF)- cytokines and implied that a cellular type 
1 reaction was responsible for psoriasis (Figure 1). The observation of the historical 
evolution of the extra-cutaneous manifestations of psoriasis and their pathogenesis confirms 
the idea of a multi-organ disease with complex immunological pathways (Scarpa et al., 
2010). 
 
Fig. 1. Time line of development of psoriasis pathophysiology: From unknown by epidermal 
problem until Immunological disease. 
3. Psoriasis: Many pieces and movements on a complex chessboard 
Psoriasis plaque is induced and maintained by multiple interactions between cells of the 
skin and immune system. It seems that the pathogenesis of psoriasis could involve a stage of 
cellular infiltration resulting in epidermal (keratinocyte) proliferation. Each inflammatory 
pathway (IL-12/Th1, IL-23/Th17, and IL-22/Th22) has its impact on psoriasis development 
(Kagami et al., 2010). The different pathways are based on the fact that T helper cells can be 
skewed towards mutually exclusive subtypes on the basis of the cytokine environment 
(Abdi, 2002; Vanaudenaerde et al., 2010). The process of T lymphocyte reactivation results 
from interaction of T cells with the resident antigen presenting cells (APCs) found in plaque 
psoriasis, which in turn determines the cytokine environment and Th1/Th17/Th22 
pathway. 
The primary etiopathogenesis of an autoimmune disease, or the activation of 
Th1/Th17/Th22 pathways, is the dysregulation of immune system activation since the 
development of autoreactive lymphocytes occurs in the same basic manner as lymphocyte 
activation. The understanding of this process or processes is very important to maintain the 
balance of the normal performance of the immune system. Briefly, it is comparable to the 
process to find the moment where one player lost the chess game based on the retroactive 
analysis of his moves. Cytokines are the possible moves of different pieces of the game. 
Many pieces can produce the same movement but with different results. The moves are the 
key players in generating/establishment of a specific immune system reaction. Therefore, 
blocking cytokines that maintain autoimmune activity has become one the most successful 
strategies for autoimmunity therapy. A new balance can be established with the removal of 
a key piece or blocking of a lethal move so that the critical players are removed from the 
chessboard of an autoimmune response. 
As with any other disease involving the immune system, psoriatic manifestation begins with 
Antigen-Presenting Cells (APC) activation by an unknown trigger. Different factors 
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including infections, trauma, medications, and emotional stress can initiate the initial phase 
of the disease. Such factors can activate keratinocytes to release cytokines such as IL-1 and 
TNF-┙, initiating the effector phase of psoriasis by activating resident skin macrophages and 
Dendritic Cells (DCs). DCs migrate to the regional lymph node, which initiates T 
lymphocyte activation in response to the stimuli. This is part of the working model of the 
immune synapse of T cells in psoriasis, integrating T cell signaling pathways in 
autoimmunity (Nickoloff & Nestle, 2004). This association leads to the production of IL-
12/Th1/IFN-┛ pathway. Many molecules in the plasma membrane of both cells, other than 
the Major Histocompatibility Complex (MHC) and T Cell Receptor (TCR), are involved in 
this phase and can be used as a target molecule for the treatment of psoriasis. The most 
important molecules are ICAM-1, LFA-3, and CD80/CD86 in the DC and LFA-1, CD2, and 
CD28 in the T cell, respectively. Alefacept, a fusion protein used for psoriasis treatment, 
blocks T cells activation by interfering with CD2 on the T cell membrane, thereby blocking 
the costimulatory molecule LFA-3/CD2 interaction (Kraan et al., 2002). Furthermore, it has 
recently been discovered that IL-27 suppressed macrophage responses to TNF-┙ and IL-1┚, 
thus identifying an anti-inflammatory function of IL-27 (Kalliolias et al., 2010). 
Continuing the evolving complex immunological chess game, the activated T lymphocyte 
Th1 cytokine producers leave the lymph node and migrate to the skin where cytokines like 
TNF-┙, produced by keratinocytes and activated DCs, facilitate T lymphocyte diapedesis 
into the dermis and epidermis (Philipp et al., 2006). The TNF-┙ induces the skin immune cell 
infiltration by inducing chemokines and upregulating adhesion molecules on the 
endothelial cells of dermal vessels. Adhesion molecules such as CLA and LFA-1 on the T 
lymphocyte membrane and E-selectin and ICAM-1 on the endothelial cell membrane are 
involved in this process. Efalizumab, a Humanized Anti-CD11a, Anti-LFA-1 molecule has 
been used in psoriasis treatment by blocking the TL migration to the skin (Sobell et al., 
2009). In summary, dendritic cells and effector T-cells are important in the development of 
the psoriastic lesion, and cytokines produced by these cells stimulate keratinocytes to 
proliferate and increase the migration of inflammatory cells into the skin, promoting 
epidermal hyperplasia and inflammation (Monteleone, G. et al., 2011). 
3.1 The chessboard: The skin influence on psoriasis development 
The primary cause of psoriasis was not found. Factors such as genetics and environmental 
exposure are now recognized to play a role in psoriasis development. Certainly, 
autoimmunity does not appear the only and necessary component to the development of 
psoriasis. However, psoriasis is a manifestation of skin immune reactions. Inflammation is a 
key feature of pathogenesis, with all inflammatory cell types implicated in psoriasis 
pathology by multiple interactions between cells of the skin or from other organs and 
immune system. Nonetheless, the etiology of psoriasis as an epidermal problem or a disease 
of faulty epidermopoiesis due to impaired autocontrol mechanisms is not completely 
wrong. Keratinocyte-derived inflammatory molecules amplificate skin immune responses 
associated with psoriasis, and contribute to the disease process and clinical phenotype 
(Albanesi & Pastore, 2010). Psoriatic keratinocytes respond aberrantly to cytokines and 
show altered intracellular signaling pathways (Endo et al., 2006). 
Heterogeneous functions of other skin resident cells, such as fibroblasts and endothelial 
cells, may also contribute to the pathogenesis of psoriasis (Albanesi et al., 2007). 
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Furthermore, leukocytes that infiltrate skin lesions have been shown to be involved in the 
pathogenesis of this disease (Chen et al., 2010). Despite parallels to the chicken and egg 
causality dilemma, all of these accounts for what later clinicians observe in patients 
suffering from psoriasis. 
4. The initial biologic treatments for psoriasis and implications on the 
understanding of immunological mechanism of psoriasis 
Psoriasis was defined as Th1 type of disease based on the early understanding of the T 
helper subsets. The initial belief was that infiltrating T cell subpopulations derived from the 
draining lymph node regulated the development of the inflammatory responses in the skin 
by producing IFN-┛ and TNF-┙ (Albanesi et al., 2005). The Th1-derived cytokines produced 
by these infiltrating Th1 favors further Th1 cell access, upregulates keratinocyte chemokine 
production, and supports dermal DC myeloid type (DC11c+) activation. In response to this 
cytokine activation, keratinocytes and other cells produce a plethora of immune mediators, 
which induce and amplify inflammatory responses in the skin (Lowes et al., 2007). 
As a result, two logical biologic therapeutic approaches were tested: one was the 
administration of counter regulatory type 2 cytokines and the second was the blocking of 
type 1 cytokines. The use of monoclonal antibodies or fusion proteins to neutralize cytokines 
started to be used on a large scale because of their efficacy and practicality.  
These studies have proved to be a useful biological model and test ground for evaluation of 
the skin immune system and psoriasis. Although these drugs were not initially developed in 
the treatment of psoriasis, but rather in rheumatoid arthritis and Crohn’s disease, the 
observation that Crohn’s disease patients with psoriasis were improving while on anti-TNF 
therapy profoundly influenced the studies that were to come (Schon & Boehncke, 2005). 
Although clinical response to anti-TNF suggested a role for Th1 cells in psoriasis, evidence 
coming from other studies demonstrated that Th1/Th2 paradigm and key role of TNF were 
not sufficient to explain the full pathogenesis of psoriasis. At this point some academic 
resistance to an immunological pathogenesis for psoriasis was raised (Nickoloff et al., 2000). 
However, the main interpretation was that an important piece of the immunological 
cytokine puzzle was missing. Many other pieces would be involved in such a complex 
game. 
5. The IL-12/23 and its role in the immunopathogenesis psoriasis 
The initial quest for the missing cytokines was the search for pathway inducers. Researchers 
first noted that IL-12 is crucial for Th1-cell differentiation (Okamura et al., 1995). IL-12 
signaling via its receptor activates Stat4 (signal transducer and activator of transcription 4), 
which upregulates IFN-┛. IFN-┛ activates Stat1, which enhance T-bet (T-box expressed in T 
cells), the leading TH1 transcription factor, further enhancing IFN- ┛ production and 
downregulating IL-4 and IL-5 expression (Biedermann et al., 2004). IFN-┛ mediates many of 
the pro-inflammatory activities of IL-12. Phagocytes and Dendritic Cells (DCs) are the main 
producers of IL-12 in response to microbial stimulation (Macatonia et al., 1995), and this 
relationship links innate resistance and adaptive immunity. The main function of IL-12 is 
resistance to infections with bacteria and intracellular parasites. However, it plays an 
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important role in the Th1 response that sustains organ-specific autoimmunity (Trinchieri, 
1998). The use of anti-IL-12 mAb (monoclonal antibody) in an experimental model of 
psoriasis also suggested the therapeutic value of blocking IL-12 in humans (Hong et al., 
2001), although side effects of the drug limited further development in this area. 
For many years, the IL-12-dependent Th1 cells were thought to be essential for the induction 
of autoimmunity. However, during the Th1/Th2 paradigm studies, an IFN-┛-independent 
mechanism responsible for the pathogenesis of many inflammatory diseases and psoriasis 
was found (Hong et al., 1999). IL-12 and IL-23, as discovered previously from human DNA 
sequence information, share the subunit p40 (Monteleone, I. et al., 2009). The use of anti-IL-
12/23p40 and anti-IFN mAb ultimately established at least part of the solution to the riddle. 
Only neutralization of p40, but not of IFN-┛, ameliorated chronic inflammatory reactions. 
This finding suggested that the latter cytokine, IL-23, accounted for the IFN-┛-independent 
mechanism of inflammation. 
Identified from human DNA sequence information, IL-23, like IL-12, is also a heterodimeric 
cytokine composed of the same subunit p40 paired with the unique p19 (Oppmann et al., 
2000). It has been reported that IL-12 and IL-23 are up-regulated in psoriatic skin (Lee et al., 
2004). Human studies with anti-IL-12p40 have shown that this treatment not only 
ameliorates psoriasis, but also down-regulates type 1 cytokines and IL-12/IL-23 in lesional 
skin (Toichi et al., 2006). Besides sharing the subunit p40 and signaling through similar 
receptors, IL-23 and IL-12 are responsible for driving different T-cell subsets. Moreover, 
presence of abundant IL-23+ dendritic cells as well as elevated mRNA expression for both 
subunits of IL-23 (IL-23p19 and IL-23p40) in psoriatic lesions supports the role of IL-23 in 
the pathogenesis of psoriasis (Lee et al., 2004; Lillis et al., 2010; Piskin et al., 2006; Wilson et 
al., 2007). Genetic studies have revealed that polymorphisms in IL-23p19, IL-12/23p40, and 
IL-23R are associated with increased risk of psoriasis (Capon et al., 2007; Cargill et al., 2007; 
Nair et al., 2009). Furthermore, in an animal xenograft model of psoriasis, Tonel G et al 
showed that treatment with anti human IL-23 mAb causes statistically significant reduction 
of acanthosis and papillomatosis index in grafts of mice in comparison to isotype controlled 
mice. Moreover, they found comparable efficacy of anti human IL-23 mAb with anti TNF-┙ 
(infliximab) in blocking the development of psoriasis. They also showed a significant 
decrease in CD3+ T cells mainly in the epidermis of mice treated with anti human IL-23 
mAb in comparison to control mice (Tonel et al., 2010). 
IL-23 could also mediate and sustain late-stage chronic inflammation by the production of 
IL-17 by Th17 (Aggarwal et al., 2003). IL-23 plays an important role as a central growth 
factor (Korn et al., 2009; Miossec et al., 2009; Romagnani et al., 2009). In presence of TGF-┚ 
and IL-6, IL-23 helps in development of Th17 cells whereas TGF-┚ is inhibitory to 
production of IL-22 (Ghoreschi et al., 2010; Volpe et al., 2008; Zheng et al., 2007) (Figure 2).  
The IL-23/Th17/IL-17 immune axis was initially elucidated when IL-17 gene expression 
was induced by B. burgdorferi independent of IL-12 (Infante-Duarte et al., 2000). The IL-17–
producing CD4+ T cells distinct from those producing either IL-4 or IFN-┛ were called Th17 
(Harrington et al., 2005). Patients with psoriasis have increased Th17 cells as well as 
increased expression of mRNA for Th17 cytokines (IL-17A; IL-17F; TNF-┙; IL-21 and IL-22) 
and chemokines (CCL20) (Boniface et al., 2007; Harper et al., 2009; Johansen et al., 2009; 
Lowes et al., 2008; Zaba et al., 2007). In psoriasis, Th17 cytokine IL-17A mainly induces 
cytokine and chemokine production by keratinocytes (Albanesi et al., 2000; Harper et al., 
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2009; Nograles et al., 2008), whereas IL-22 induces proliferation of keratinocytes and 
production of antimicrobial peptides by keratinocytes (Liang et al., 2006; Sa et al., 2007; 
Wolk et al., 2006; Zheng et al., 2007). The role of IL-23 and IL-17 in psoriasis was further 
substantiated in some animal studies with recombinant IL-23 and anti IL-17A. In wild type 
(WT) mice, injection of recombinant murine (rm) IL-23 induces epidermal hyperplasia 
(Chan et al., 2006; Kopp et al., 2003), whereas, in IL-17 -/- mice showed less epidermal 
hyperplasia after repeated injection of rmIL-23. A recent publication by Rizzo et al showed 
that WT mice do not show epidermal hyperplasia to injection of rmIL-23 if they were treated 
with anti IL-17A antibodies (Rizzo et al., 2011). A redundant cytokine model has emerged as 
the evolving explanation for psoriasis pathogenesis. It is based on the IL-12/Th1/ IFN-┛ - 
TNF- and the IL-23/Th17/IL-17 immune pathways (Figure 3). The effectiveness of the 
anti-TNF treatment of psoriasis validated the first axis. The efficacy of anti-p40 (anti-
IL12/23) treatment confirms the other (Nestle et al., 2009). 
 
Fig. 2. The pivotal role of some of IL-12 and IL-23 in psoriasis etiopathogenesis: How 
blocking the effects of these cytokines substantially improve the disease condition. 
 
Fig. 3. Time line of development of psoriasis pathophysiology: From complex 
Immunological disease by genetic participation until recent advances. 
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6. Selective IL-23/Th17/IL-17 immune axis inhibition 
IL-23 favors the proliferation of the Th17 subtype and consequent production of IL-22 and 
IL-6 that stimulates the proliferation of keratinocytes. IL-17 favors infiltration of neutrophils 
into the skin forming the typical Munro’s micro-abscesses with some participation of IL-22 
(Watanabe et al., 2009). 
Studies have demonstrated that anti-p40 (anti-IL-12/23) treatment is highly efficacious for 
psoriasis. Ustekinumab anti IL-12/23 antibody showed its efficacy and safety in three phase 
III trials recruiting 2899 patients. From two placebo controlled trials, PHOENIX 1 and 
PHOENIX 2, ustekinumab showed its efficacy in ameliorating psoriatic plaques, pruritus, 
and nail psoriasis (Yeilding et al., 2011). (Table 1).  
 
* P <0.001 Adapted from: Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, 
a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a 
randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371(9625):1675-1684. 
Table 1. Clinical improvement at week 12 (PHOENIX II) 
Remarkably, in a phase II multicenter, randomized, double-blind, placebo-controlled trial 
briakinumab, another human monoclonal anti-IL-12/23 antibody, 90-93% of subjects in 4 
dosing groups were able to achieve a PASI 75 (Lima et al., 2009a). This finding alone 
confirms the centrality of this pathway because these levels of efficacy have not been 
previously seen in studies with other agents (Leonardi et al., 2008). Safety data for both 
agents is limited, but to date has been favorable. 
One issue with anti-p40 therapy is that it inhibits both the classical IL-12/Th1/IFN-┛ and IL-
23/Th17/IL-17 immune pathways. IL-12 and IL-23 are related cytokines with differences in 
their biological activities. After binding to their receptors, different intracellular 
transcription complexes are activated (Parham et al., 2002). IL-12 predominantly acts on 
naïve T cells and initiates the TH1 response. In contrast, IL-23 primarily affects memory T 
cells and expands the initiated Th1 inflammatory response by Th17 activity and maintains 
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an adequate memory pool by compromising memory T cells (Oppmann et al., 2000; Parham 
et al., 2002; Trinchieri et al., 2003). Experimental studies suggest that IL-23/Th17/IL-17 
immune axis blocking is sufficient to treat autoimmune inflammation (Monteleone, I. et al., 
2009).  
Another way to block both pathways is the immunoregulatory role of IFN-┛. It is well-
known that the administration of anti-IFN-┛ induces exacerbation of Experimental 
Autoimmune Encephalomyelitis (EAE) (Becher et al., 2002). One possible explanation is the 
inhibition of IL-12/Th1/IFN-┛ axis may destroy the regulatory role of IFN-┛ during chronic 
inflammation. TNF-, like INF-┛, has a regulatory role in the immune system (Liu et al., 
1998). This might explain the observation that anti-TNF therapies can induce psoriasis and 
other autoimmune diseases in some patients (Ramos-Casals et al., 2008). 
An increase in efficacy and reduction of adverse events are the main drivers for new 
therapies. Infections, one type of adverse event, usually increase in patients receiving anti-
cytokine therapy (Dinarello, 2003). Studies with anti-IL-23 therapy will require surveillance 
for the development of opportunistic infections. Reports from patients with IL-12 and/or IL-
23 cytokine deficiency syndromes alert to these potential infections in individuals under 
anti-IL-23 therapy. Invasive salmonellosis and mycobacterial diseases were present more 
often in patients with IL-12/IL-23 deficiency indicating that immunity against these 
microorganisms appears to be dependent of IL-12 and/or IL-23 (MacLennan et al., 2004). 
However, antibodies against IL-12 and IL-23 may not cause a complete inactivity of these 
cytokines in a clinical scenario. For example, an experimental study showed that IL-23 plays 
a role in host defense against P. carinii, but it is not an essential one (Rudner et al., 2007). 
Clinical studies with anti-IL-12/23 treatment thus far have not increased the risk of non 
opportunistic or opportunistic infections (Shear et al., 2008). A recent study showed that 
blocking IL-23 with monoclonal antibodies during BCG infection does not appear to affect 
the bacterial burden in immunocompetent mice. In contrast, blocking TNF- or both IL-23 
and IL-12 with anti-p40 dramatically enhances mycobacterial growth. From this study, 
antibody blockade of IL-23 alone rather than IL-12 might be preferable in patients who have 
been, or may be, exposed to mycobacterial infection (Chackerian et al., 2006). 
7. A new piece and a new move 
As previously mentioned, the IL-23 favors the proliferation of the Th17 and consequent 
production of IL-22. IL-22 mRNA presence was initially described in IL-9 stimulated T-cell 
lines and in concanavalin A (Con-A)-activated murine spleen cells (Dumoutier et al., 2000). 
Further studies demonstrated that IL-22 expression can only be observed in activated 
immunological cells (Wolk et al., 2002). However, other reports have revealed that some T 
cells express IL-22 independently of IL-17 (Nograles et al., 2009). Finally, a new distinct 
human memory CD4+ T cell subset with skin-homing properties was identified and 
denominated Th22 (Duhen et al., 2009). 
A preferential production of IL-22 cytokine by T cells (Th22, Th17, and Th1) is present in 
psoriasis lesions (Lowes et al., 2008). Many animal models indicate the role of IL-22 in 
psoriasis. IL-22 over-expressed transgenic mice developed psoriasis-like skin lesions (Wolk 
et al., 2009a). In IL-22 -/- mice, injection of IL-23 fails to induce epidermal hyperplasia 
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indicating the role of IL-22 as a downstream mediator of tissue effects caused by IL-23 
(Zheng et al., 2007). In a recent publication, Rizzo HL et al showed that to have IL-23 
mediated epidermal hyperplasia, both IL-17 and IL-22 is required; any one of these is not 
sufficient to execute the effect of IL-23. They also showed that pre-treatment with anti IL-22 
or anti IL-17A Abs block the rmIL-23 mediated epidermal hyperplasia in wild type mice 
(Rizzo et al., 2011). In reconstituted epidermis model, IL-22 produces acanthosis dose 
dependently, which resembles psoriasis and either one of these alone is not sufficient to 
execute the effect of IL-23. The effects of IL-20 subfamily cytokines on reconstituted human 
epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive 
immunity in psoriasis (Sa et al., 2007). In a study by Wolk K et al, a correlation was 
demonstrated between the plasma IL-22 levels and the severity of the disease (Wolk et al., 
2006). IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular 
differentiation, and mobility in keratinocytes and may play a: a potential role in psoriasis 
(Wolk et al., 2006). Moreover, IL-22 levels correlated with IL-20 levels, which is in 
accordance with the IL-22-induced keratinocyte IL-20 production (Wolk et al., 2009b). This 
suggests that IL-22 and its downstream mediator IL-20 play an important role in the final 
steps of psoriasis pathogenesis. Sabat R and his group in their studies showed that IL-22 
regulates keratinocyte function in several ways: a. IL-22 helps form a biological barrier of 
the skin by producing antimicrobial proteins (AMPs) like ┚-defensins, and S100 proteins. 
This may be one of the reasons that psoriatic patients have less skin infections. b. IL-22 
interferes with physiological desquamation process of skin by inhibiting the terminal 
differentiation of keratinocytes. c. IL-22 plays a role in recruiting neutrophilic granulocytes 
in skin by inducing the production of chemokines;. d. IL-22 indirectly helps in extracellular 
tissue degradation by inducing production of matrix metalloproteinases 1 and 3. IL-22 
induces the production of IL-20, another IL-10 family cytokine which has similar effects as 
IL-22, thus resulting in amplification of the effects of IL-22 (Sabat & Wolk, 2011). In a 
transgenic mouse model, it has been showed that IL-22 causes acanthosis, hyperkeratosis, 
and hypogranulosis, which are hallmarks of psoriasis. IL-22 acts through STAT-3 to 
impact the differentiation of keratinocytes (Wolk et al., 2009a). IL-22 induces pro-
inflammatory chemokines and antimicrobial proteins (AMPs) ┚-defensins (BDs), and 
promotes epidermal acanthosis and parakeratosis of keratinocytes (Boniface et al., 2005; 
Wolk et al., 2004; Wolk et al., 2006). Some synergistic effect was noted with other pro-
inflammatory cytokines like TNF-┙; IFN-┛; and IL-17 (Sabat & Wolk, 2011). Alone, TNF- ┙ 
does not have much effect on terminal differentiation of keratinocytes, but when 
keratinocytes were co-cultured with IL-22 and TNF- ┙, the effects of IL-22 were amplified. 
This kind of synergism was also seen with CXCL8 and IL-20 expression in keratinocytes 
co-stimulated with IL-22 & TNF-┙. One possible explanation of this may be that TNF-┙ 
increases the expression of IL-22 receptor complex and also affects the IL-22 signaling 
pathway (Wolk et al., 2009a). Thus, IL-22 and IL-20, but not IFN-┛ or IL-17, are the key 
mediators of resulting epidermal proliferation. IL-22 acts through heterodimeric receptor 
complex composed of IL-22R1 and IL-10R2 (Kotenko et al., 2001). IL-10R2 chain is 
ubiquitously expressed in all cells and is important component of receptor complexes 
required for IL-22, IL-10, IL-26 and IL-28 and IL-29, whereas the IL-22R1 chain is present 
in epithelial cells and hepatocytes (Savan et al., 2011). Between the two subunits, IL-22 
binds first to IL-22R1, the high-affinity receptor, and then IL-10R2, a lower affinity 
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receptor (Jones et al., 2008). To produce its effect, IL-22 acts through different signaling 
pathways, mainly signal transducer and activator of transcription 3 (STAT-3) and mitogen 
activated protein kinase (Lejeune et al., 2002). 
This final move induces the vicious cycle of proliferation and inflammation of the skin 
characterized by the hyper-proliferative phenotype of keratinocytes in psoriasis. An anti-IL-
22/ IL-20 approach would have a complementary role to the neutralization of p40. 
However, there has not yet been a human study to demonstrate such a role or anti-IL-22 
therapy in the treatment of psoriasis.  
8. The other side of the chessboard: The role of Treg 
Today, reading a book or scientific article on immunopathogensis, one will observe that 
suppressor T cells, renamed regulatory T cells (Tregs), have become a central concept in 
immunological vocabulary (Horwitz et al., 2002). Hundreds of publications on Tregs have 
validated the existence of this single line of T cells. The CD4+CD25+highFoxp3+ Treg 
subpopulation is developed in the thymus and may be peripherally induced during the 
course of a normal immune response. The model in which Tregs directly or indirectly 
modify activation and differentiation of pathogenic T cells by means of an effect on antigen-
presenting cells is supported by in vivo analyses (Korn et al., 2010). 
8.1 Regulatory T cells: Development of an immunological concept 
Biological systems are subject to complex regulatory controls and the immune system is no 
exception. It is known that the immune system has the potential to generate lymphocytes 
against auto-antigens. Experiments, however, suggest that individuals cannot easily be 
immunized against their own tissues. Therefore, a suppression mechanism is necessary to 
control potentially pathogenic immune cells. Owen suggested that this tolerance against 
one's own tissues is acquired during the development of the immune system, and Burnet 
proposed that the clonal selective destruction of lymphocytes for auto-antigens occurs 
primarily in the thymus. 
The destruction of auto-reactive lymphocytes is the primary mechanism that leads to 
tolerance, but we know that this system is not perfect. Self-reactive B and T lymphocytes 
can be isolated from normal individuals (Ramsdell & Fowlkes, 1990). Nishizuka and 
Sakakura proposed another mechanism for controlling auto-reactive cells. They observed 
that mice thymectomized between the second and fourth days of life developed an organ-
specific autoimmune disease. This target-organ destruction can be prevented by restoring 
T cells from genetically identical individuals. The generation of regulator T cells was 
proposed in order to explain this mechanism of auto-tolerance attributed to the thymus 
(Sakaguchi et al., 1996). 
Other studies observed that the prevention of autoimmune diseases was diminished by 
the reduction of CD4+ T cells, but not of CD8+ T cells, indicating that regulatory cells 
belonged to the CD4+ T cell class of lymphocytes. Sakaguchi subsequently characterized 
these regulatory cells as natural CD4+CD25+ Tregs that express Foxp3 (Sakaguchi et al., 
2001). 
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8.2 Suppressor T cells: Regulatory T cells are suppressor T cells 
Another control point of the immune response is established when the normal immune 
response is initiated. A different mechanism must be set off in order to control the 
magnitude of the response and its subsequent termination. This regulation should 
contribute to limiting clonal expansion and effector cell activity. Soon after the discovery 
that T lymphocytes function as helper cells for B-lymphocytes, RK Gershon proposed that 
they could also act as cells capable of suppressing the immune response (Gershon & Kondo, 
1971). This subpopulation of suppressor T cells was considered a controller of both auto-
reactive and effector cells. A suppressor cell was functionally defined as a lymphocyte that 
inhibits the immune response by influencing the activity of another type of cell involved in a 
cascade of suppression factors, a network of anti-idiotypic T cells, and counter-suppressive 
cells (Dorf & Benacerraf, 1984). 
Many of the experiments carried out contain data that support the existence of suppressor T 
cells. However, the mechanism responsible for these suppressive phenomena was never 
clearly characterized, and consequently interest in the field of suppressor T cells has 
gradually dwindled. The discovery of Th1/Th2 cells led researchers to abandon the concept 
of suppressor T cells. Suppression was instead attributed to counter-regulatory cytokines. 
As pointed out by Green and Webb, the letter ‘‘S'' started to resemble a foul word in cellular 
immunology, and its use was considered synonymous of scarce data with excessive 
interpretation or a mystic phenomenon (Green & Webb, 1993). 
Suppressor T cells reappeared as regulatory T cells (Tregs) in the late 1990s when several 
subpopulations of T cells were identified as having the capacity to inhibit the proliferation 
of other cells. Shevach et al. were the first to call attention to the fact that regulatory T cells 
and suppressor T cells are the same (Shevach et al., 1998). Therefore, the term ‘regulatory' 
gradually replaced the term ‘suppressor'. The main problem, however, is not that cells are 
termed regulatory, but that they are considered to be suppressors. It is more appropriate to 
consider regulatory T cells as immune response directors instead of its suppressors. 
9. Regulatory T cells and psoriasis 
The regulation mechanism of the immune system by CD25+high Tregs is not well 
understood. Studies have not yet arrived at a simple mode of action. Whatever the 
mechanism, the homeostatic balance of the immune system is obtained by healthy cellular 
and humoral responses. Some inflammatory agents, whether physical, chemical, or 
infectious, induce an intense immune response. This immune response against them 
frequently results in tissue damage that could be more intense if it were not for the 
interference of regulatory mechanisms (Belkaid et al., 2006). As has already been 
specified, Treg cells help limit the damage caused by a vigorous immune response. 
Natural Treg cells may respond to an ample variety of auto-antigens, although there is 
evidence that they may also respond to antigens expressed by microbes. Induced 
regulatory T cells, such as TR1 or Th3, may develop from CD4+ T cells when exposed to 
specific conditions (Weiner et al., 2011). 
Similarly, excessive activity of Treg cells may limit the magnitude of the immune response, 
which may result in failure to control an infection. On the other hand, the absence of the T 
regulator may result in intense inflammation and autoimmune dermatitis. Tissue damage 
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may also result from the development of effector cells against their own auto-antigens 
(Figure 4). 
 
Fig. 4. Immune response regulation mechanisms. The force balance between Tregs and the 
effector T CD4+ cells may present in a different manner depending on being an autoantigen 
or a pathogen. In A portion, the clinical expression of autoimmune skin diseases is shown. 
In this case, there is clinical manifestation only when the number and function of Tregs are 
significantly reduced. B portion displays clinical manifestations that may occur in extreme 
cases. In case of excessive Treg function, the result shows reduction of effector lymphocytes 
against the pathogen, an increase in its number and less tissue damage. The contrary applies 
to effector cells against the pathogen that surpass the number and function of Treg. The 
ideal immune and clinical response occurs when there is a balance between functions 
Psoriasis is sustained by the activation of pathogenic T cells. The regulatory expression of 
skin diseases discusses the action exerted by regulatory T cells, especially CD4+CD25+high 
Tregs on psoriasis. Various types of influence of these cells suggest that they may act by 
suppressing or augmenting immunity (Sabat et al., 2007; Shehata & Elghandour, 2007). The 
control of Treg cells may affect the results favorably or may be deleterious. There is no 
definitive view. In psoriasis, studies have shown that the subpopulation of CD4+ T 
lymphocytes in peripheral blood, phenotypically CD25+high, CTLA-4(+), Foxp3high, is 
deficient in its suppressor functions. This is associated with an accelerated proliferation of 
the CD4+ T cell response (Sugiyama et al., 2005). The presence of non-functional 
CD4+CD25+high Treg cells in peripheral blood and in tissues may lead to a reduced 
capacity to contain pathogenic T cells and to a hyperproliferation of the psoriatic plaque in 
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vivo. These findings represent a critical component of this autoimmune disease and may 
have implications for potential therapy by manipulation of CD4+CD25+high Tregs in vivo. 
However, other factors, such as the immune status and genotype, and the presence of 
concomitant diseases or other infections may also have an influence. The manipulation of 
this balance can be explored therapeutically. 
9.1 Clinical and therapeutic consequences of regulatory T cells 
An improved understanding of the role of T regulators in psoriasis may lead to the 
identification of new targets for treatment. More specifically, the goal is to manipulate 
natural regulator cells or those induced by means of an increase or decrease of their 
function, depending on the circumstances. 
Auto-injections of regulatory T cells are a promising approach to modulation of 
inflammation and autoimmune diseases (Wilhelm et al., 2010). Nevertheless, there is a 
significant decline in the function of natural CD4+CD25+high Treg cells of peripheral blood 
in patients with autoimmune diseases when compared to that of healthy individuals. In 
order to overcome this difficulty, cytokines were used to stimulate the growth of regulator T 
cells. IL-15 allows a significant in vitro expansion of regulator cells (Ortega et al., 2009). 
Natural CD4+CD25+high Treg cells obtained by ex vivo expansion through stimulation with 
allogeneic antigen-presenting cells and IL-2 were capable of modulating the graft-versus-
host disease (GVHD). Induction of natural CD4+CD25+high Treg cells may facilitate the 
establishment and maintenance of immunological tolerance. Depletion of natural 
CD4+CD25+high Treg cells may be an effective way of reversing the tolerance induced by 
malignant tumors and increasing the activity of the immune system against cancer epitopes 
(Yu et al., 2005) 
In the field of dermatology, the stimulation of Treg cells may be important in autoimmune 
diseases. For example, blockage of T lymphocyte stimulation, as in the use of the antibody 
associated with CTLA-4 (cytotoxic T lymphocyte-associated antigen 4-immunoglobulin, 
CTLA4Ig), reverts the development of psoriatic plaques (Abrams et al., 2000). In the clinical 
context, the effect of immunomodulator drugs on these cells warrants attention. For 
example, tacrolimus, an inhibitor of calcineurin, increases the inhibition of Treg cells in 
atopic dermatitis (Sewgobind et al., 2010; Vukmanovic-Stejic et al., 2005). Fludarabine 
reduces the frequency and suppressive function of natural CD4+CD25+high Treg cells (de 
Rezende et al., 2010). Low doses of cyclophosphamide induce the inhibition of natural 
CD4+CD25+high Treg cells and consequently increase the immune response in an 
apparently paradoxical effect (Lutsiak et al., 2005). Along the same line, cyclophosphamide 
decreases the function, proportion, and number of natural CD4+CD25+high Treg cells that 
suppress the induction of contact hypersensitivity (Cerullo et al., 2011; Ikezawa et al., 2005). 
Currently, topical corticosteroids constitute one of the most effective treatments for psoriasis 
and other inflammatory skin diseases. These drugs are effective in inhibiting the function of 
Th2 cells, eosinophils, and epithelial cells. However, treatment with these drugs during the 
presentation of the epitope may result in an increased tolerance by suppressing the 
development of dendrite cells that secrete IL-10, which are necessary for the induction of T 
regulators. Therefore, treatment with corticosteroids may increase the subsequent effect of 
the T response and aggravate, on the long run, the course of inflammatory diseases (Stock et 
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al., 2005). This aspect may also be related to the rebound effect of inflammatory diseases 
once these drugs are removed. 
10. Conclusion 
In medicine, a gold standard is the intervention believed to be the best available option. 
Given the proven role of many cytokines in psoriasis, substantial interest exists in targeting 
them with neutralization immunotherapy. If Th1/Th17/Th22 pathways operate in different 
steps of psoriasis development, then targeted blockade place biologics as the standard-
setting paradigm for therapy and understanding of the pathogenesis of psoriasis. However, 
large studies are needed to provide information on the therapeutic effects, adverse events of 
any anti-cytokine therapy, and their place in the treatment of psoriasis and other skin 
diseases. To complement this approach, a detailed comprehension of the associations among 
the various regulator cells may help in understanding the events leading to the genesis of 
skin diseases. Ultimately, an ability to manipulate the function of regulator T cells according 
to the desired therapeutic effect will be the goal. Together, an integrated immunologic 
approach to therapy holds great promise in reducing the burden of psoriatic disease.  
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